Gail Boudreaux
CIK 1287920 · President and CEO · last filed 2026-07-17
Gail Boudreaux is a President and CEO who has filed 141 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing shows the insider bought $1.0M of ELV on Jul 17, 2026. Across all open-market trades the lifetime net is −$36.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $152.0M across reported positions. 44 SEC filings were submitted jointly with ZIMMER BIOMET HOLDINGS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
UNH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
INDIANAPOLIS, IN 46204
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELV | President and CEO | 169,991 | $432.93 | $73.59M | -$13.59M | 8 | 2026-07-17 |
| TGT | Director | 12,192 | $147.74 | $1.80M | $0 | 6 | 2026-03-13 |
| Elevance Health, Inc. (ANTM) Delisted | President and CEO | 94,041 | $482.58 | $45.38M | $2.00M | 6 | 2022-03-03 |
| ZBH | Director | 2,095 | $96.59 | $202.4K | $250.0K | 41 | 2021-04-02 |
| ANTX | President and CEO | 11,104 | $3.54 | $39.3K | $0 | 1 | 2018-03-05 |
| XEL | Director | 1,780 | $77.71 | $138.3K | $50.0K | 29 | 2018-01-02 |
| NVAX | Director | 10,000 | $9.15 | $91.5K | $144.8K | 4 | 2017-03-20 |
| UNH | EVP & CEO, UnitedHealthcare | 184,731 | $411.12 | $75.95M | -$24.88M | 39 | 2014-09-25 |
| GENZ | Director | 5,000 | $37.11 | $185.6K | $0 | 6 | 2011-04-06 |
Recent Filings
141 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-17 | ELV | Buy (P) | +2,725 | $1.00M | EDGAR |
| 2026-03-13 | TGT | Grant (A) | +2,682 | $0 | EDGAR |
| 2026-03-04 | ELV | Mixed | +18,231 | -$2.47M | EDGAR |
| 2025-07-18 | ELV | Buy (P) | +8,500 | $2.44M | EDGAR |
| 2025-03-14 | TGT | Grant (A) | +2,946 | $0 | EDGAR |
| 2025-03-05 | ELV | Mixed | +15,811 | -$4.11M | EDGAR |
| 2024-07-23 | ELV | Sell (S) | −34,000 | -$17.03M | EDGAR |
| 2024-07-22 | ELV | Notice (144) | −34,000 | -$17.03M | EDGAR |
| 2024-03-15 | TGT | Grant (A) | +1,873 | $0 | EDGAR |
| 2024-03-05 | ELV | Mixed | +23,676 | -$9.61M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.